SUNY Downstate Medical Center
450 Clarkson Avenue
Room A2-523 (cardiac cath lab)
Brooklyn, NY 11203-2098
Cell: 917-885-8854 more contact information

Artherosclerosis is currently understood to be an inflammatory disease so biomarkers are likely to play an increasingly important role in our understanding and management of the disease.

Dr. Marmur and his colleagues hold patents on novel biomarkers that have the ability to predict future adverse events such as myocardial infarction and death. Recent publications in this area have focused on the roles of TIMP-1, Adiponectin and RANTES ( Am Heart J 2006, Eur Heart J 2006).

See an example of the predictive power of the TIMP-1 biomarker reported in 2006 in the American Heart Journal.

Platelets
Dr. Marmur holds a patent on the role of F11R, a junctional adhesion molecule that mediates platelet binding to inflamed endothelium.

His work on the molecular biologic responses to vascular injury mediated by platelet-derived growth factor (PDGF) led to the seminal observation that the tissue factor (TF) gene is induced by balloon angioplasty ( J Clin Invest 1993).

Further work in this area was supported by NIH funding, and resulted in a number of novel observations, including the first report that active TF is present in human coronary arteries, and the first generation of a viral vector to inhibit TF gene expression ( Circulation 1996, Circulation 2002).

Dr. Marmur is also a major contributor to the field of platelet glycoprotein IIb/IIIa inhibitors. Recently, he has articulated the position that IIb/IIIa inhibitors should be given using a bolus-only strategy.

Coagulation Cascade
Dr. Marmur was the first to report thrombin generation in humans during coronary angioplasty ( J Am Coll Cardiol 1994). One of Dr. Marmur's major contributions is the idea that low molecular weight heparin can and should be monitored during percutaneous coronary intervention ( J Invasive Cardiol 2006). He has reported that both enoxaparin and dalteparin significantly and predictably elevate the activated clotting time (ACT) after intravenous administration ( J Am Coll Cardiol 2003, J Invasive Cardiol 2005).

Dr. Marmur is one of the early pioneers in the application of recombinant DNA and viral vector technologies to human arterial disease. (AGENT trial, Ribozyme paper).

Dr. Marmur recognizes that future advances are most likely to be derived from the field of genomics and the related subfields of functional genomics, proteomics, and bioinformatics.

His efforts focus on the generation of the Downstate Cath Lab Database, a repository of molecular genetic, angiographic and historical information on at least 2000 patients who have undergone cardiac catheterization.